Today brings exciting news for the rare disease community, born from immense effort, patient advocacy, and a refusal to back down. In a historic move, Metachromatic Leukodystrophy (MLD) and Duchenne Muscular Dystrophy (DMD) have been officially added to the federal Recommended Uniform Screening Panel (RUSP).
In a year defined by uncertainty, this is a monumental win for families. However, the path taken to get here highlights a critical need for policy reform within the Department of Health and Human Services (HHS).
The Road to a Breakthrough in Newborn Screening
The path to this announcement was anything but standard. In April 2025, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC)—the body responsible for conducting vigorous evidence reviews for the RUSP—was unexpectedly disbanded by HHS. This left both the MLD and DMD communities in limbo. They had undergone months of intense meetings and evidence reviews, only to have the finish line moved at the last moment.
Rather than waiting for a broken system to fix itself, these communities took a novel approach: they published their evidence reviews, presented the evidence in cooperation with the EveryLife Foundation. They used that evidence to appeal directly to the HHS Secretary, who holds the ultimate authority to add conditions to the federal screening list even when an advisory committee exists.
What RUSP Inclusion Means for Families
This victory translates directly into lives saved and improved health outcomes. Because of this designation:
- Widespread State Screening: The clock has begun; we can expect to see most states screening for both conditions within the next five years.
- Early Adoption: We expect to see many states adopt these conditions within the next three years, depending on their individual RUSP-alignment status and requirements.
- Life-Saving Early Intervention: For MLD and DMD, where time is of the essence, early detection is the difference between permanent disability and the opportunity for treatment.
Why the Current Path is Not Sustainable for Public Health
While we celebrate this achievement, we must be honest: this is not a sustainable way to conduct public health policy. Going directly to the Secretary was a necessary “Plan B,” but it cannot be the standard for rare disease advocacy.
Without the passage of the Newborn Screening Saves Lives Reauthorization Act, we lack a permanent federal advisory committee. Without an expert committee, there is no mechanism to provide the rigorous, evidence-based reviews these decisions require. We cannot rely on political maneuvers for every rare condition. To protect the integrity of the screening process, we need:
- An Advisory Committee: To ensure scientists, clinicians, and experts are reviewing conditions.
- An Evidence-Based Approach: To remove politics from the process of saving children’s lives.
- Legislative Stability: Through the formal reauthorization of the Act by Congress.
Strategy for the Future of Newborn Screening
Today, we celebrate with the MLD and DMD communities. Tomorrow, we continue the work.
We remain committed to advocating for a Newborn Screening condition addition process that is as reliable and scientific as the screenings themselves.
Patient Advocacy Strategies is ready to help your organization navigate this changing landscape and strategize your state-by-state Newborn Screening approach. Together, we can ensure that no community is left behind by a changing political tide.
